1. The Protective Effect of Testosterone on the Ovarian Reserve During Cyclophosphamide Treatment
- Author
-
Masae Yoo, Hiromi Konishi, Kazumasa Komura, Akiko Tanabe, Kohei Taniguchi, Tomohito Tanaka, Masahide Ohmichi, and Masami Hayashi
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Cyclophosphamide ,business.industry ,Follicular atresia ,Granulosa cell ,Testosterone (patch) ,Premature ovarian insufficiency ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Endocrinology ,Oncology ,Apoptosis ,In vivo ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Pharmacology (medical) ,Ovarian reserve ,business ,medicine.drug - Abstract
Introduction Cyclophosphamide, which is widely used to treat malignant disease, causes ovarian follicular atresia, which leads to premature ovarian insufficiency. The present study evaluated the protective effect of testosterone in preventing the decline in the ovarian reserve during cyclophosphamide treatment. Methods Using the COV434 human granulosa cell line, the protective effect of testosterone against cyclophosphamide was evaluated by immunocytochemistry, Western blotting and an MTS assay. The follicles in mouse ovaries and serum anti-Mullerian hormone were also assessed to evaluate the effects of testosterone. Results Testosterone suppressed the decrease in cell viability and apoptosis caused by cyclophosphamide treatment in vitro. In vivo, the number of atretic follicles in the mouse ovary was significantly lower in the testosterone plus cyclophosphamide group than in the cyclophosphamide alone group (p=0.03). The serum anti-Mullerian hormone was significantly higher in the testosterone plus cyclophosphamide group than in the cyclophosphamide alone group (16.2 [9.7-22.6]) vs 11.2 [8.9-12.1], p
- Published
- 2020